Switzerland Innovation



新药研发 Drug Discovery 瑞士制造 Made in Switzerland


Based on an innovative strategic partnership agreed between the Chinese President and the President of the Swiss Confederation in 2016, SWITZERLAND INNOVATION cordially invites you to the Drug Discovery Event at the Novartis Campus in Shanghai.


在瑞士创新园,科学与医药行业之间的跨学科合作密切无间、蓬勃发展,进而揭开直击精准药物的关键和途径,推动新药研发进入新时代。瑞士创新园携手瑞士驻华大使馆瑞士贸易与投资处,致力于推动瑞士成为研发创新之国。罗氏、诺华和爱可泰隆(被强生收购)等国际巨头扎根瑞士,并在此设立全球研究中心。其他领先的生物技术和制药公司,其中不乏众多美国公司,同时也包括AC Immune、Alnylam、安进、百健、蓝鸟、复星、绿叶制药、Prothena或Tesaro,也纷纷选择瑞士作为研发基地。诺华和罗氏作为瑞士本土巨擘,吸引全球的高科技人才纷至沓来。

About the Event:

Drug discovery has come a long way from guess work to a structural and targeted approach to finding new and better remedies. In order to see the big picture and to develop new drugs, companies need to stay up to date about the latest discoveries in genomics, proteomics, structural or quantitative biology. The industry must translate the scientific efforts into a new innovative product.

At SWITZERLAND INNOVATION, such interdisciplinary collaborations between science and industry can flourish, thus finding keys and  pathways to more precise medicine and bring drug discovery into a new era. Together with the Swiss Business Hub China, SWITZERLAND INNOVATION is committed to promote Switzerland as a location for R&D and innovation. International corporations such as Roche, Novartis and Actelion (J&J), have their home base and global research centers in Switzerland. Other leading biotech and pharmaceutical companies — many of them from the US — including AC Immune, Alnylam, Amgen, Biogen, Bluebird, Fosun, Luye Pharma, Prothena or Tesaro have chosen Switzerland as an R&D location. Together with Novartis and Roche as the incumbent players, they attract many highly skilled experts from all over the world.

活动流程 Program Rundown:
14.00 – 14.30 登记 Registration
14.30 – 15.30 主题发言 Key note speaches: Prof. Christoph Hock and Prof. Michael Hennig
15.30 – 16.30 讨论 Panel Discussion
16.30 – 18.00 交流 Networking


Christoph Hock教授(医学博士)

  • 苏黎世大学医学副校长
  • 苏黎世大学施利伦校区再生医学院主任
  • 临床科学家,协会认证精神病医师,临床试验研究者


Michael Hennig教授(博士)

  • 在巴塞尔F. Hoffman – La Roche AG从事研究管理,
  • 具有长达20年的新药研发专业经验
  • 巴塞尔大学结构生物学客座教授
  • 结构生物学家,高级制药新药研发主管
  • 企业家,leadXpro AG联合创始人

Hennig教授是生物科技公司leadXpro AG的首席执行官和董事会主席,该公司位于瑞士创新

About the Speakers:

Professor Christoph Hock, MD

  • Co-director of the Institute of Regenerative Medicine (IREM) at the University of Zurich
  • Clinician and clinical trialsinvestigator
  • Vice President for Medicine at University of Zurich

Prof. Hock is the co-founder and board member of  Neurimmune. The biopharmaceutical company partnered its lead program in Alzheimer’s disease with Biogen in 2007 and developed a recombinant human monoclonal antibody targeting the neurodegenerative process in Alzheimer’s disease.

Professor Michael Hennig, PhD

  • 20 years of drug discovery expertise from research management at F. Hoffmann – La Roche AG Basel.
  • Guest Professor for structural biology at the University of Basel
  • Structural biologist and senior Pharma drug discoveryexecutive
  • Entrepreneur, co-founder of leadXpro AG

Prof. Hennig is CEO and Chairman of the Board of the Biotech company leadXpro AG, located at the Switzerland Innovation Park innovaare. The company is committed to structure and biophysical methods based drug discovery on membrane protein targets. Key areas of research include the use of large research facilities such as Swiss Light Source (SLS) Swiss Free Electron Laser (SwissFEL) and single particle cryo_Electron Microscopy (cryo-EM). leadXpro’s research activities are focused on the lead discovery for better cancer treatments and antibiotics with new mechanisms of action.


We look forward to welcoming you and invite you to RSVP before November 20. Please send your confirmation of your attendance to Ms. Weng: xinyun.weng@eda.admin.ch

期待您的到来。11 月 20 日前,敬请赐复。
诺华集团    如欲参加,请向翁女士

着装要求 Dress code: 正装 Formal




诺华集团 上海市浦东新区金科路 4218 号 Novartis Campus Shanghai, Jinke Road 4218, Pudong



IP Management photo


Intellectual property (IP) is as indispensable for a company’s success as innovation itself. Proper IP management can significantly improve a company’s position on the market, help it stand out from its competitors and increase its value. IP management is particularly important at the interface between science and industrial research, where progress often depends on technology transfer. To help you optimize your IP management and discuss best practices, we invite you to join our half-day workshop dedicated to this highly relevant subject.


Workshop topics

Our workshop participants will become acquainted with the general framework and success factors for efficient IP management. Presentations will feature practical examples from the industry that are as interesting as they are diverse. In “break-out” sessions, participants will be able to contribute their own questions to the dialogue. The workshop will conclude with practical tips on how to review and pragmatically (continue to) develop one’s own IP strategy.

  • Global trends in IP Management
  • Value generation through IP management
  • Basic terms and safeguards
  • Implementation of property rights in other countries, dealing with disputes
  • Evaluation of technologies and patents
  • Patent strategy and patent management
  • IP management in R&D collaborations
  • Licensing and exploitation
  • Patent portfolio management, internal policies
  • Cost optimization, handling of a few legally protected patents
  • Weaknesses and practical measures to overcome them
  • Instruments against piracy and counterfeiting
  • IP management and patent protection in an international context

More about the agenda, speakers, and practical examples read here.


8:00 - 13:00